6 Jun 2025 • A new randomized trial in 784 chronic kidney disease (CKD) and type 2 diabetes patients on renin–angiotensin inhibitors found that combined finerenone and empagliflozin therapy reduced urinary albumin-to-creatinine ratio (UACR) by 29% more than finerenone alone (mean ratio 0.71) and 32% more than empagliflozin alone (mean ratio 0.68) at 180 days.

The dual treatment was well tolerated, with low rates of hyperkalemia and acute kidney injury.

These results support early co-initiation of both agents to maximize kidney protection in this high-risk group.

Source: The New England Journal of Medicine homepage | Read Full Story